LUV TRZ

A 39-residue acylated synthetic peptide characterized in cryo-EM structural studies of class B GPCR complexes.

View Luv TRZ in the store

Molecular Profile

Type
Synthetic peptide (acylated, 39 residues)
Molecular formula
C225H348N48O68
Molecular weight
~4,810.5 g/mol
CAS number
2023788-19-2
Amino acids
39
Fatty acid chain
C20 diacid
Modification
Aib at positions 2 and 13; Lys20 acylated with a C20 fatty-diacid via a spacer linker; modifications confer protease resistance and albumin binding.

Mechanism & Target Class

A 39-residue synthetic peptide. Two Aib residues at positions 2 and 13 confer protease resistance; the C20 fatty-diacid chain on Lys20, attached via a spacer, promotes reversible albumin binding and extends the peptide's circulating half-life. Signaling studies characterize its engagement of class B1 G protein–coupled receptors, including Gαs–cAMP coupling and receptor internalization behavior.

Storage & Handling

Lyophilized
-20°C (-80°C long term); lyophilized powder stable ~3 years.
Handling
Prepare stock solutions fresh; protect from light; keep sealed and dry.

Primary Database

PubChem CID 163285897 ↗

References (21)

  1. Reviews

    1

    Galindo RJ, et al. (2025). Diabetes Therapy

    DOI: 10.1007/s13300-025-01804-wPubMed 41196501

  2. 2

    Zhou Q, et al. (2023). Diabetology & Metabolic Syndrome

    DOI: 10.1186/s13098-023-01198-4PubMed 37904255

  3. 3

    Min T, et al. (2021). Diabetes Ther

    DOI: 10.1007/s13300-020-00981-0PubMed 33325008

  4. 4

    Forzano I, et al. (2022). Int J Mol Sci

    DOI: 10.3390/ijms232314631PubMed 36498958

  5. 5

    Tang Y, et al. (2022). Front Pharmacol

    DOI: 10.3389/fphar.2022.1016639PubMed 36569320

  6. 6

    Lin F, et al. (2023). PLoS One

    DOI: 10.1371/journal.pone.0285197PubMed 37141329

  7. Clinical

    7

    Thomas MK, et al. (2021). J Clin Endocrinol Metab

    DOI: 10.1210/clinem/dgaa863PubMed 33236115

  8. 8

    Rosenstock J, et al. (2021). Lancet

    DOI: 10.1016/S0140-6736(21)01324-6PubMed 34186022

  9. 9

    Frías JP, et al. (2021). N Engl J Med

    DOI: 10.1056/NEJMoa2107519PubMed 34170647

  10. 10

    Ludvik B, et al. (2021). Lancet

    DOI: 10.1016/S0140-6736(21)01443-4PubMed 34370970

  11. 11

    Heise T, et al. (2022). Lancet Diabetes Endocrinol

    DOI: 10.1016/S2213-8587(22)00085-7PubMed 35468322

  12. 12

    Jastreboff AM, et al. (2022). N Engl J Med

    DOI: 10.1056/NEJMoa2206038PubMed 35658024

  13. 13

    Loomba R, et al. (2024). N Engl J Med

    DOI: 10.1056/NEJMoa2401943PubMed 38856224

  14. 14

    Malhotra A, et al. (2024). N Engl J Med

    DOI: 10.1056/NEJMoa2404881PubMed 38912654

  15. 15

    Packer M, et al. (2025). N Engl J Med

    DOI: 10.1056/NEJMoa2410027PubMed 39555826

  16. Primary research

    16

    Rees TA, et al. (2024). Frontiers in Pharmacology

    DOI: 10.3389/fphar.2024.1463313PubMed 39464637

  17. 17

    Zhao F, et al. (2022). Nature Communications

    DOI: 10.1038/s41467-022-28683-0PubMed 35217653

  18. 18

    Sun W, et al. (2022). Proceedings of the National Academy of Sciences

    DOI: 10.1073/pnas.2116506119PubMed 35333651

  19. 19

    Willard FS, et al. (2020). JCI Insight

    DOI: 10.1172/jci.insight.140532PubMed 32730231

  20. 20

    Coskun T, et al. (2018). Molecular Metabolism

    DOI: 10.1016/j.molmet.2018.09.009PubMed 30473097NCT02759107

  21. 21

    El K, et al. (2023). Nat Metab

    DOI: 10.1038/s42255-023-00811-0PubMed 37277609